Abstract

Ponesimod (Ponvory) is a new sphingosine 1‐phosphate receptor modulator for the treatment of adults with relapsing forms of multiple sclerosis (MS). This article discusses its mode of action, efficacy and adverse effects.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call